Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.

In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (AMBT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTI...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakhani, S., Selby, P., Bliss, J. M., Perren, T. J., Gore, M. E., McElwain, T. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971420/
https://www.ncbi.nlm.nih.gov/pubmed/1690022
_version_ 1782134906338410496
author Lakhani, S.
Selby, P.
Bliss, J. M.
Perren, T. J.
Gore, M. E.
McElwain, T. J.
author_facet Lakhani, S.
Selby, P.
Bliss, J. M.
Perren, T. J.
Gore, M. E.
McElwain, T. J.
author_sort Lakhani, S.
collection PubMed
description In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (AMBT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTIC) combination. The high dose treatments and the combination chemotherapy resulted in significantly higher response rates but no prolongation of survival. Factors associated with longer survival included the absence of visceral metastases, the absence of bulky disease and good performance status. For all treatments, life table estimates of survival at 1 and 2 years were only 10% and 4% respectively.
format Text
id pubmed-1971420
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19714202009-09-10 Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Lakhani, S. Selby, P. Bliss, J. M. Perren, T. J. Gore, M. E. McElwain, T. J. Br J Cancer Research Article In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (AMBT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTIC) combination. The high dose treatments and the combination chemotherapy resulted in significantly higher response rates but no prolongation of survival. Factors associated with longer survival included the absence of visceral metastases, the absence of bulky disease and good performance status. For all treatments, life table estimates of survival at 1 and 2 years were only 10% and 4% respectively. Nature Publishing Group 1990-02 /pmc/articles/PMC1971420/ /pubmed/1690022 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Lakhani, S.
Selby, P.
Bliss, J. M.
Perren, T. J.
Gore, M. E.
McElwain, T. J.
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
title Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
title_full Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
title_fullStr Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
title_full_unstemmed Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
title_short Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
title_sort chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971420/
https://www.ncbi.nlm.nih.gov/pubmed/1690022
work_keys_str_mv AT lakhanis chemotherapyformalignantmelanomacombinationsandhighdosesproducemoreresponseswithoutsurvivalbenefit
AT selbyp chemotherapyformalignantmelanomacombinationsandhighdosesproducemoreresponseswithoutsurvivalbenefit
AT blissjm chemotherapyformalignantmelanomacombinationsandhighdosesproducemoreresponseswithoutsurvivalbenefit
AT perrentj chemotherapyformalignantmelanomacombinationsandhighdosesproducemoreresponseswithoutsurvivalbenefit
AT goreme chemotherapyformalignantmelanomacombinationsandhighdosesproducemoreresponseswithoutsurvivalbenefit
AT mcelwaintj chemotherapyformalignantmelanomacombinationsandhighdosesproducemoreresponseswithoutsurvivalbenefit

Ejemplares similares